Authors
Latest:
Expert highlights cybersecurity regulation updates for health care organizationsThere have been several recent regulatory updates related to cybersecurity in health care.
Latest:
iRARC adoption is slow but persistent in bladder cancer"Over the past 10 to 15 years, tremendous efforts have gone into robotic surgical innovation to improve perioperative morbidity for patients with bladder cancer undergoing RC," write Andrew M. Wood, MD, and Nima Almassi, MD.
Latest:
Going “retro”: A perspective on robotic retroperitoneal renal surgeryImprovements in technology have renewed interest in the technique.
Latest:
Strategies to mitigate impact of intravenous ICM shortage"The global shortage of ICM has necessitated rapid adaptation of workflows and clinical pathways, which are particularly important for practicing urologists who are evaluating patients for hematuria," write Yair Lotan, MD, and colleagues.
Latest:
Kevin Zorn, MD, on the potential impact of inconsistent compensation for BPH surgery“Certainly, I think when you have these inherent challenges or biases in the reimbursement aspects, it has to beg the question, does this or how will this impact the future of acquisition or passing down of these newer technologies?” says Kevin C. Zorn, MD, FRCSC, FACS.
Latest:
Advantages and limitations of AI in prostate cancerInterest in AI in prostate cancer pathology has picked up speed since initial attempts of computer-aided diagnosis of the disease more than a decade ago, according to Peter A. Humphrey, MD, PhD.
Latest:
Future Directions in Prostate Cancer TreatmentDrs Smith and Helfand look ahead and provide their thoughts on future directions in the treatment of patients with prostate cancer.
Latest:
Asked by a Resident: Dr. Efe Chantal Ghanney Simons interviews Dr. Mark S. Litwin"The most important thing I feel I've learned in my life so far is the value of human interaction and human connection," says Mark S. Litwin, MD, MPH.
Latest:
Future Directions in PSMA-PET ImagingLooking to the future treatment landscape in prostate cancer, the panel provides closing thoughts on the trajectory of the utilization of PSMA-PET imaging and the unmet needs it might address.
Latest:
Multidisciplinary Care in Prostate CancerIn the second article of this series, Ryan A. Hankins, MD, and Sean P. Collins, MD, PhD, discuss multidisciplinary care practices in prostate cancer, with a focus on communication across specialties.
Latest:
Conventional and next-generation imaging evaluation of biochemically recurrent prostate cancer"The incorporation of NGI into the BCR disease state definition necessitates a consensus within the medical community," write Spyridon P. Basourakos, MD, and Jack R. Andrews, MD.
Latest:
5 ways health care practices can mitigate cyberattack riskIn the world of health care, factors such as remote care, complex IT environments, and connected health care devices are creating new avenues for cybercriminals to target.
Latest:
Urologic implications of Lynch syndromeResearch indicates Lynch syndrome is associated with urothelial, prostate, and other urologic cancers.
Latest:
What is genetic discrimination, and why does it matter?Fear of discrimination has downstream effects on health care.
Latest:
Expert shares advice for ethical adoption of AI in health care“Responsible application of AI is crucial, especially when the health and well being of people are at stake,” writes industry expert Manny Krakaris.
Latest:
Is now a good time to sell your medical practice to a private equity group?Industry expert provides in-depth advice.
Latest:
Strategies for dealing with difficult patientsIn this article, an expert addresses the most common issues that come up with patients that may make them harder to deal with and solutions that may help a provider.
Latest:
Management of hormone-naïve oligometastatic prostate cancerGrowing evidence supports the existence of an intermediate metastatic disease state.
Latest:
Drug interactions to monitor when prescribing erectile dysfunction medicationsMany of the medications used in the treatment of ED have interactions with other medications, so it is crucial to carefully examine patient profiles to optimize therapy and ensure safety.
Latest:
Enhancing Patient-Centric Management in OAB in 2024 and BeyondPanelists conclude their discussion by reflecting on key learnings and sharing advice for patient-centric management in overactive bladder (OAB) treatment, specifically focusing on effective communication and overlooked aspects of patient care. They offer guidance to other providers on enhancing patient experiences, particularly with procedures like Botox. The episode wraps up with each expert sharing their final thoughts and anticipations for advancements in OAB treatment in 2024, highlighting their commitment to addressing patient needs in this evolving field.
Latest:
Michigan Institute of Urology opens dedicated outpatient medical center for minimally invasive health careThe center will offer a comprehensive range of treatments, including prostate artery embolization for men suffering from benign prostatic hyperplasia with very large prostates.
Latest:
The safety and oncologic benefits of transperineal vs transrectal MRI-guided prostate biopsy"These studies, taken together, offer important insight into the direction we should be heading in prostate cancer diagnosis: toward a targeted-only TP biopsy," write Tarik Benidir, MD, and Zeyad Schwen, MD.
Latest:
Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination TherapyPanelists discuss their views on using cretostimogene as monotherapy versus combination therapy, the importance for urologists to stay updated on advances for managing BCG-unresponsive NMIBC, and the potential impact of combining cretostimogene with pembrolizumab on addressing unmet needs in NMIBC care.
Latest:
As Patients Live Longer, New Criteria Needed for Prostate Cancer TrialsResearchers sought to understand if a lack of cancer progression as monitored by radiography could substitute overall survival as a metric for metastatic prostate cancer clinical trials.
Latest:
Encouraging antitumor activity seen with neoadjuvant enfortumab vedotin in patients with cisplatin-ineligible MIBC“This first disclosure of data supports the ongoing phase 2 and 3 programs evaluating enfor-tumab vedotin alone or in combination with pembrolizumab in MIBC,” said Daniel P. Petrylak, MD.
Latest:
Gautam Jayram, MD, on key bladder cancer agents to keep an eye on"There's a ton of activity in this space, and I think every 6 to 12 months, we're going to keep getting these boluses of information that's going to help us," says Gautam Jayram, MD.
Latest:
Update offers clues to optimal olaparib use in prostate cancerThe latest findings for the PARP inhibitor in prostate cancer come from an analysis of the pivotal phase 3 PROfound trial presented during the 2021 AUA Annual Meeting.
Latest:
Bladder preservation in localized, muscle-invasive bladder cancer: Current state of affairs“In the highly selected patient with localized MIBC, an organ-preserving approach to treatment may produce similar oncologic outcomes to radical surgery with a potential for improved QoL, although there is currently insufficient evidence to recommend bladder preservation therapy as a standard of care," the authors write.
